{"id":"NCT00412529","sponsor":"Novartis Pharmaceuticals","briefTitle":"Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B","officialTitle":"A Randomized, Open-label, Controlled, Multicenter, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine (LDT600) 600 mg or Entecavir (ETV) 0.5 mg Given Over 12 Weeks on the Kinetics of Hepatitis B Virus (HBV) DNA in Adults With HBeAg-positive, Compensated Chronic Hepatitis B (CHB)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-02","completion":null,"firstPosted":"2006-12-18","resultsPosted":"2011-08-12","lastUpdate":"2015-03-13"},"enrollment":44,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis B","Chronic Hepatitis B"],"interventions":[{"type":"DRUG","name":"Entecavir","otherNames":[]},{"type":"DRUG","name":"Telbivudine","otherNames":[]}],"arms":[{"label":"Telbivudine","type":"EXPERIMENTAL"},{"label":"Entecavir","type":"ACTIVE_COMPARATOR"}],"summary":"This exploratory study is designed to determine the early viral kinetic profile during treatment with telbivudine or entecavir at multiple time points over 12 weeks.","primaryOutcome":{"measure":"Change in Mean Hepatitis B Virus (HBV) DNA Levels","timeFrame":"Baseline (day 1) to Week 12 (day 85)","effectByArm":[{"arm":"Telbivudine","deltaMin":10.29,"sd":1.6477},{"arm":"Entecavir","deltaMin":9.721,"sd":1.7141}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":8,"countries":["South Korea"]},"refs":{"pmids":["20028815"],"seeAlso":["http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826006/?tool=pubmed"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":23},"commonTop":["Alanine aminotransferase increased","Upper respiratory tract infection","Blood creatine phosphokinase increased","Nausea"]}}